Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brompheniramine is a first-generation antihistamine of the alkylamine class used to relieve symptoms associated with allergies and the common cold such as sneezing, runny nose, itchy or watery eyes. It acts primarily as an antagonist (more accurately an inverse agonist) at histamine H1 receptor and also exhibits moderate antimuscarinic (anticholinergic) activity. This dual action helps reduce allergic symptoms but can cause side effects like drowsiness and dry mouth. Brompheniramine is typically administered orally and is well absorbed from the gastrointestinal tract. It was first approved in 1957 for medical use[1][2][3][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on brompheniramine.